Trial Profile
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-135 (JSC BIOCAD, Russia) in Patients With Advanced Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Manelimab (Primary)
- Indications Adenocarcinoma; Bladder cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Biocad
- 19 Mar 2018 New trial record